These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35861513)

  • 1. Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis.
    Tomelleri A; Rinaldi E; Campochiaro C; Picchio M; Dagna L
    Rheumatology (Oxford); 2023 Feb; 62(2):e24-e26. PubMed ID: 35861513
    [No Abstract]   [Full Text] [Related]  

  • 2. [Does tocilizumab mean the end of glucocorticoids in giant cell arteritis?].
    Samson M; Bonnotte B
    Rev Med Interne; 2018 Feb; 39(2):75-77. PubMed ID: 29217104
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of giant cell arteritis: what is in the pipeline?].
    Holle JU; Moosig F
    Z Rheumatol; 2020 Aug; 79(6):516-522. PubMed ID: 32399619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. My Treatment Approach to Giant Cell Arteritis.
    Garvey TD; Koster MJ; Warrington KJ
    Mayo Clin Proc; 2021 Jun; 96(6):1530-1545. PubMed ID: 34088416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of Tocilizumab in Giant-Cell Arteritis.
    Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schett G; Schulze-Koops H; Spiera R; Unizony SH; Collinson N
    N Engl J Med; 2017 Jul; 377(4):317-328. PubMed ID: 28745999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-term use of tocilizumab in giant cell arteritis.
    Coath FL; Mukhtyar C
    Rheumatology (Oxford); 2021 Oct; 60(10):4447-4449. PubMed ID: 33956087
    [No Abstract]   [Full Text] [Related]  

  • 7. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Villiger PM; Adler S; Kuchen S; Wermelinger F; Dan D; Fiege V; Bütikofer L; Seitz M; Reichenbach S
    Lancet; 2016 May; 387(10031):1921-7. PubMed ID: 26952547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab for the maintenance of glucocorticoid-free remission in a patient with giant cell arteritis and psoriatic arthritis.
    Rotar Ž; Tomšic M; Hocevar A
    Rheumatology (Oxford); 2018 May; 57(5):934-936. PubMed ID: 29394408
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppressive treatment for giant cell arteritis: where do we stand?
    Pipitone N; Salvarani C
    Clin Exp Rheumatol; 2015; 33(2 Suppl 89):S-5-6. PubMed ID: 26016749
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic effectiveness of upadacitinib combined with glucocorticoid on remission induction and maintenance in giant cell arteritis.
    Sanada A; Abe N; Bohgaki M; Kasahara H
    Rheumatology (Oxford); 2022 Aug; 61(9):e274-e276. PubMed ID: 35357433
    [No Abstract]   [Full Text] [Related]  

  • 11. Giant cell arteritis: new concepts, treatments and the unmet need that remains.
    Coath F; Gillbert K; Griffiths B; Hall F; Kay L; Lanyon P; Luqmani R; Mackie SL; Mason JC; Mills J; Mollan S; Morgan AW; Mukhtyar C; Quick V; Watts R; Dasgupta B
    Rheumatology (Oxford); 2019 Jul; 58(7):1123-1125. PubMed ID: 30423174
    [No Abstract]   [Full Text] [Related]  

  • 12. Polymyalgia Rheumatica and Giant Cell Arteritis.
    Buttgereit F; Matteson EL; Dejaco C
    JAMA; 2020 Sep; 324(10):993-994. PubMed ID: 32897333
    [No Abstract]   [Full Text] [Related]  

  • 13. Tocilizumab and glucocorticoids for giant cell arteritis: the learning curve.
    Mackie SL; Bhogal R
    Lancet Rheumatol; 2023 Dec; 5(12):e703-e705. PubMed ID: 38251559
    [No Abstract]   [Full Text] [Related]  

  • 14. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.
    Hoffman GS; Cid MC; Rendt-Zagar KE; Merkel PA; Weyand CM; Stone JH; Salvarani C; Xu W; Visvanathan S; Rahman MU;
    Ann Intern Med; 2007 May; 146(9):621-30. PubMed ID: 17470830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of primary vasculitides with biologic and novel small molecule medications.
    Serling-Boyd N; Wallace ZS
    Curr Opin Rheumatol; 2021 Jan; 33(1):8-14. PubMed ID: 33164993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in the treatment of giant cell arteritis.
    Leuchten N; Aringer M
    Immunotherapy; 2018 Mar; 10(6):465-472. PubMed ID: 29504436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Treatment of Giant Cell Arteritis in Different Clinical Settings.
    Pfeil A; Oelzner P; Hellmann P
    Front Immunol; 2018; 9():3129. PubMed ID: 30733723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Giant cell arteritis: An updated review of an old disease.
    Rinden T; Miller E; Nasr R
    Cleve Clin J Med; 2019 Jul; 86(7):465-472. PubMed ID: 31291180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory giant cell arteritis on prednisone and tocilizumab: improvement with subsequent tuberculosis reactivation.
    Kherani I; Chin C; Kherani RB; Kherani F
    Can J Ophthalmol; 2019 Aug; 54(4):e192-e194. PubMed ID: 31358167
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.